MitoQ & Cardiopulmonary Responses During Exercise

September 29, 2023 updated by: Ball State University

The Acute Effects of Mitochondrial Antioxidant Supplementation on Metabolic Flexibility

Study Purpose: To examine the acute effects of antioxidant supplementation on energy use during a single bout of exercise in apparently healthy adult men and women.

Specifically this study examined the acute effect of MitoQ on:

  1. cardiopulmonary responses to submax and maximal exercise
  2. Energy expenditure and fat/carbohydrate oxidation during sub maximal exercise.

In a double-blind, randomized, placebo controlled, cross-over study design, participants performed 2 experimental trials which differed only in the supplement consumed (MitoQ or Placebo). Participants performed identical exercise protocols which consisted of a series of submaximal workloads followed by a ramp protocol to volitional exhaustion.

Study Overview

Status

Completed

Conditions

Detailed Description

Participants performed the following 3 study visits:

Visit 1 consisted of baseline resting measures including blood pressure and blood vessel health, blood biomarkers, and body composition assessments.

Visits 2 and 3 were the acute supplementation intervention(s) with either MitoQ or Placebo in a randomly designed order. These visits included an assessment of blood pressure and blood vessel health and an exercise test on a stationary cycle. There was a minimum of 48-72 hours between trials 2 and 3.

Visit 1

  • Participants arrived at the laboratory fasted from all food and drink other than water for at least 12 hours. The following assessments were performed:
  • Informed consent and health history questionnaire
  • Resting heart rate, handgrip strength, and body composition
  • Resting electrocardiogram (ECG)
  • Blood biomarkers (Total cholesterol, HDL, LDL-C, and triglycerides as well as fasting blood glucose and HbA1c).
  • Blood pressure

Visit 2 & 3 (performed in a randomized order differing only in the supplement consumed)

Acute supplementation intervention(s)

  • The night before both the Placebo and MitoQ trials, participants were asked to eat the same meal at the same time of night and were provided with a standard Ensure shake to consume at 8:00pm the night before each trial.
  • Upon arrival, they rested supine for ~10 minutes before consuming supplement (MitoQ or Placebo)
  • Following consumption of the supplement or placebo, participants completed a graded aerobic exercise protocol. This test involved riding on a stationary cycle to exhaustion. The total test duration was ~30-45 minutes which included a break to rest between the submax and maximal portions. Heart function was monitored with an electrocardiogram (ECG). A gas analysis cart was used to determine the composition of the air breathed in and out during the test for the determination of substrate oxidation rates and VO2max. Heart rate was measured continuously throughout the exercise protocol from the ECG. Rate of perceived exertion (RPE) was measured every minute and blood pressure (BP) was performed every third minute of the exercise protocol. Additional measures of blood lactate via a finger stick were performed during the exercise protocol.

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Indiana
      • Muncie, Indiana, United States, 47306
        • Ball State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Be greater than or equal to 18 years of age
  • Have a resting seated systolic blood pressure (SBP) of less than 160 mmHg and diastolic blood pressure (DBP) less than 100 mmHg
  • Nonsmoker
  • Body mass index (BMI) less than or equal to 35 kg/m2
  • Considered physically inactive defined as participating in <150 min/week of moderate physical activity or <75 minutes/week of vigorous activity (ACSM).

Exclusion Criteria:

  • participants that cannot complete the exercise protocol or have any signs/symptoms suggestive of cardiovascular or metabolic disease.
  • Individuals that are currently on beta blockers
  • diagnosed with type II diabetes will be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Gelatin capsules
Gelatin capsules
Experimental: MitoQ
Commercially available MitoQ (80mg)
80mg of MitoQ taken in one dose on one occasion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiorespiratory fitness
Time Frame: acutely (1 hr)
VO2max
acutely (1 hr)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ventilation
Time Frame: acutely (1hr)
L/min
acutely (1hr)
Heart rate
Time Frame: acutely (1 hr)
beats per minute
acutely (1 hr)
Blood pressure
Time Frame: acutely (1hr)
mmHg
acutely (1hr)
Maximal Fat Oxidation rate
Time Frame: acutely (1hr)
g/min
acutely (1hr)
Peak blood lactate
Time Frame: acutely (1hr)
mmol
acutely (1hr)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 14, 2022

Primary Completion (Actual)

April 30, 2023

Study Completion (Actual)

April 30, 2023

Study Registration Dates

First Submitted

September 25, 2023

First Submitted That Met QC Criteria

September 29, 2023

First Posted (Actual)

October 5, 2023

Study Record Updates

Last Update Posted (Actual)

October 5, 2023

Last Update Submitted That Met QC Criteria

September 29, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 1946841-3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Placebo

3
Subscribe